Gebauer B, Bohnsack O, Riess H
Klinik für Strahlenheilkunde, Charité, Universitätsmedizin,
Rofo. 2011 Aug;183(8):695-703. doi: 10.1055/s-0029-1246074. Epub 2011 Mar 9.
Radiological-morphological response evaluation plays a major role in oncological therapy and studies for approval. Specific criteria have been developed for some tumor entities and chemotherapeutics. Application, limitations and definitions of the most frequently used criteria for tumor response evaluation will be presented.
Review based on a selective literature research.
In clinical oncological therapy studies, WHO and RECIST are the most frequently used criteria to evaluate morphological therapy response. RECIST criteria have been modified recently, especially with respect to the evaluation of lymph nodes, and were published as RECIST 1.1 in 2009. All criteria were originally developed and defined to review clinical multicenter trials for approval. Using these criteria in a clinical situation, certain limitations have to be considered. To evaluate response, a baseline scan before therapy start is mandatory. Special tumor response criteria have been defined for some certain tumor entities. Oncologists and radiologists should define in advance which criteria are used before starting therapy.
The use of defined criteria is very important in oncology response evaluation. In-depth knowledge of the criteria and their limits is required for correct usage.
放射形态学反应评估在肿瘤治疗及审批研究中起着重要作用。已针对某些肿瘤实体和化疗药物制定了特定标准。将介绍肿瘤反应评估最常用标准的应用、局限性及定义。
基于选择性文献研究进行综述。
在临床肿瘤治疗研究中，WHO和RECIST是评估形态学治疗反应最常用的标准。RECIST标准最近已修订，尤其是在淋巴结评估方面，并于2009年作为RECIST 1.1发布。所有标准最初都是为审查临床多中心试验以获得批准而制定和定义的。在临床情况下使用这些标准时，必须考虑某些局限性。为评估反应，治疗开始前的基线扫描是必需的。已为某些特定肿瘤实体定义了特殊的肿瘤反应标准。肿瘤学家和放射科医生应在开始治疗前预先确定使用哪些标准。
在肿瘤反应评估中使用明确的标准非常重要。正确使用需要深入了解这些标准及其局限性。
